dorsaVi has extended its agreement with Medtronic for a further 6 months, worth an additional US$171,000 following the continued success of their partnership.
The agreement extension, on top of a US$330,000 master service agreement (MSA) signed in March 2021, is aimed at optimising the technology and build on insights from the ongoing agreement.
dorsaVi will continue to leverage its technology in the data capture and analysis workstreams, leading to an optimised, customisable product, in line with Medtronic’s objectives.
“Different potential uses of our technology”
dorsaVi chief executive officer Andrew Ronchi said: “We are excited to continue developing our relationship with Medtronic.
“The extension of our agreement is testament to the hard work of our team and is a strong validation of our world-leading technology.
“We will continue to invest in this partnership and build upon our growing foundation.
“This agreement further highlights the different potential uses of our technology, exploring new applications and potential partnerships to deliver shareholder value.”
Innovative motion analysis device technologies
dorsaVi is focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety.
Headquartered in Dublin, Ireland, Medtronic is among the world’s largest medical technology, services and solutions companies - alleviating pain, restoring health, and extending life for millions of people around the world.
The partnership further validates dorsaVi’s technology, as Medtronic continues to rely on the data-driven insights generated by dorsaVi to deliver better patient outcome.